Alzheimer’s Trial Failures May Be Due to Compound That Promoted Amyloid Buildup, Study Says

Alzheimer’s Trial Failures May Be Due to Compound That Promoted Amyloid Buildup, Study Says
Researchers may have discovered the reason certain investigational therapies failed in Alzheimer’s disease clinical trials — a finding that could lead to new trials with a greater chance of success, according to a study published in the journal Cell Reports. A class of drugs, intended to block an enzyme involved in the production of the

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *